Fintel reports that on October 29, 2025, Wedbush initiated coverage of Opus Genetics (NasdaqCM:IRD) with a Outperform ...

Check the CBSE Class 11 Biotechnology Deleted Syllabus 2025–26 to know the removed topics from key units and practicals.

But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. There are plenty of strategies for discovering value stocks, but we have ...

The average one-year price target for Opus Genetics (NasdaqCM:IRD) has been revised to $6.94 / share. This is a decrease of ...

At Rutgers NJMS, art and music are helping future doctors strengthen empathy, sharpen observation skills and bring humanity to patient care.

From scaling labs to launching AI-driven tools, Mitilenes has tackled evolving market needs with a focus on outcomes.

Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Emergent Biosolutions (EBS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Mr Quilty said while producers could look forward to an increase in prices towards the second half of 2026, the existing ...